Shanghai Henlius Biotech Announces First EU Patient Dosed in Phase 2 HLX43 Clinical Trial for Advanced NSCLC
Key Developments in Advanced Non-Small Cell Lung Cancer (NSCLC) Therapy
Shanghai Henlius Biotech, Inc. (2696.HK) has announced a significant milestone in its international clinical development program, with the first patient in an EU country (Spain) dosed in the ongoing multicentre Phase 2 clinical trial of HLX43 for injection. HLX43 is an innovative anti-PD-L1 antibody-drug conjugate (ADC) being investigated for the treatment of advanced non-small cell lung cancer (NSCLC). This marks a major advancement for the company as it expands its clinical trial footprint globally, including Chinese Mainland, the United States, Australia, Japan, and now Europe.
Highlights for Investors
- Global Expansion: The Phase 2 clinical study of HLX43 is now active in Spain (EU), Chinese Mainland (excluding Hong Kong, Macau, and Taiwan), the US, Australia, and Japan.
- Clinical Trial Design & Objectives:
- The trial is open-label, multi-centre, and international, focusing on efficacy and safety evaluation in patients with advanced NSCLC.
- Consists of two parts: Part 1 identifies the optimal HLX43 dose, and Part 2 is a single-arm efficacy assessment.
- The primary endpoint is the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria.
- About HLX43:
- HLX43 is a novel antibody-drug conjugate (ADC) targeting PD-L1, developed in-house, with a topoisomerase I inhibitor payload and a proprietary peptide linker.
- Indications under investigation include advanced/metastatic solid tumours, with ongoing studies in NSCLC, metastatic colorectal cancer (mCRC), cervical cancer (CC), and esophageal squamous cell carcinoma (ESCC).
- In combination regimens (HLX43+HANSIZHUANG, HLX43+HLX07), the product is being trialed for other advanced solid tumour indications.
- Clinical Data to Date:
- Phase 1 results presented at the 2025 ASCO and WCLC meetings demonstrated good safety and encouraging efficacy in several solid tumours, including NSCLC.
- In heavily pre-treated NSCLC patients (median ≥3 prior lines of therapy), HLX43 showed a promising ORR of 37.0% and a disease control rate (DCR) of 87.0%.
- Phase 2 data in cervical cancer (ESMO Asia 2025): ORR of 41.4% overall, and up to 70% at the 3.0mg/kg dose.
- Phase 2 data in ESCC (ASCO GI 2026): ORR of 30.3% overall, and 61.5% at the 3.0mg/kg dose.
- HLX43 is considered biomarker-independent, potentially expanding patient eligibility and market reach.
- Market Condition & Competitive Landscape:
- Currently, no antibody-drug conjugate targeting PD-L1 has been approved for marketing globally, making HLX43 a potential first-in-class agent if successful.
- The results and ongoing progress position Henlius at the forefront of innovative cancer immunotherapies.
Important Considerations for Shareholders
- The advancement of HLX43 into Phase 2 trials internationally, especially in the EU, is a price-sensitive development that could impact market sentiment and the company’s valuation.
- Strong clinical data, especially in patient populations with high unmet needs, supports the potential for HLX43 to become a major product if approved.
- Risk Statement: The company cautions that there is no guarantee HLX43 will successfully complete development or gain regulatory approval, and investors should monitor ongoing trial results and regulatory updates closely.
Conclusion
With the first EU patient dosed in the HLX43 Phase 2 international clinical trial, Shanghai Henlius Biotech has reached a critical inflection point in its push to advance novel oncology therapies for global markets. Positive efficacy and safety signals from earlier studies, combined with a competitive position as a potential first-in-class anti-PD-L1 ADC, make this development highly noteworthy for investors. Shareholders should remain vigilant, as subsequent trial outcomes and regulatory milestones may have significant implications for the company’s future growth and share price.
Disclaimer
The above article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own due diligence and consult professional advisors before making investment decisions. The clinical development process involves risks and uncertainties, and there is no assurance that HLX43 will ultimately receive regulatory approval or achieve commercial success.
上海復宏漢霖生物技術有限公司 HLX43 國際多中心二期臨床研究關鍵進展
重要投資者資訊及潛在股價影響
上海復宏漢霖生物技術有限公司（2696.HK）近日宣佈，公司自主研發的創新型抗PD-L1抗體偶聯藥物（ADC）HLX43，用於治療晚期非小細胞肺癌（NSCLC）的國際多中心二期臨床研究，在歐盟國家（西班牙）成功給予首位患者用藥。這標誌著公司全球研發佈局的又一重大里程碑，目前該研究已在中國內地（不含港澳台）、美國、澳洲、日本及歐洲同步展開。
投資重點摘要
- 全球多中心擴展： HLX43二期臨床試驗已在歐盟（西班牙）、中國內地、美國、澳洲及日本展開。
- 臨床設計及目標：
- 開放標籤、多中心、國際二期臨床，聚焦於晚期NSCLC患者的療效與安全性評估。
- 分為兩部分：第一部分探索最佳劑量，第二部分為單臂療效評估。
- 主要終點： 由BICR根據RECIST v1.1評估的客觀緩解率（ORR）。
- HLX43 產品詳情：
- HLX43為自主研發ADC，結合新型拓撲異構酶I抑制劑與專利肽鏈連接。
- 適應症包括晚期/轉移性實體瘤，涉及NSCLC、mCRC、子宮頸癌、食管鱗癌等多個領域。
- 組合療法（HLX43+漢斯狀、HLX43+HLX07）用於其他實體瘤研究。
- 現有臨床數據：
- 一期數據在2025年ASCO及WCLC會議公佈，展示良好安全性及積極療效。
- 多線治療失敗NSCLC患者中，ORR 37.0%，疾病控制率87.0%。
- 子宮頸癌二期（ESMO Asia 2025）：總體ORR 41.4%，3.0mg/kg組達70%。
- 食管鱗癌二期（ASCO GI 2026）：總體ORR 30.3%，3.0mg/kg組達61.5%。
- HLX43屬生物標誌物非依賴型ADC，潛在覆蓋患者更廣。
- 市場環境與競爭格局：
- 目前全球尚無針對PD-L1的抗體偶聯藥物獲批上市，HLX43具有首創潛力。
- 若後續數據優異，將提升公司在腫瘤免疫治療領域的國際競爭力。
股東需注意事項
- HLX43國際二期臨床的推進，尤其歐洲納入首位患者，屬重大且敏感信息，或將影響市場評價及股價表現。
- 早期臨床數據積極，若最終能獲批有望成為重磅新藥。
- 風險提示： 公司強調HLX43尚未保證能成功完成註冊及上市，投資者應密切關注後續臨床進展及監管動態。
結語
隨著HLX43國際二期臨床在歐盟首位患者用藥，上海復宏漢霖在創新腫瘤免疫治療的全球化進程邁出重要一步。現有數據顯示其安全性及療效具備競爭優勢，若最終上市或成為全球首個PD-L1靶向ADC。投資者應密切留意後續臨床及監管節點，因其或對公司未來增長及股價產生重大影響。
免責聲明
以上內容僅供參考，並不構成投資建議。投資者應自行作出審慎判斷，並諮詢專業意見。新藥研發具有高度不確定性，HLX43最終能否上市仍存風險。
